HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here’s What You Need To Know – Pliant Therapeutics (NASDAQ:PLRX)
HC Wainwright & Co. has decided to maintain its Buy rating of Pliant Therapeutics PLRX and lower its price target from $52.00 to $48.00. Shares of Pliant Therapeutics are trading…